Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar
Laith J. Abu‐Raddad, Hiam Chemaitelly, Roberto Bertollini
New England Journal of Medicine (2022) Vol. 386, Iss. 11, pp. 1091-1093
Open Access | Times Cited: 105

Showing 1-25 of 105 citing articles:

Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
Heba N. Altarawneh, Hiam Chemaitelly, Houssein H. Ayoub, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 1, pp. 21-34
Open Access | Times Cited: 475
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
Laith J. Abu‐Raddad, Hiam Chemaitelly, Houssein H. Ayoub, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 19, pp. 1804-1816
Open Access | Times Cited: 363
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
Hiam Chemaitelly, Houssein H. Ayoub, Sawsan AlMukdad, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 214
Antibody-mediated neutralization of SARS-CoV-2
Henning Gruell, Kanika Vanshylla, Timm Weber, et al.
Immunity (2022) Vol. 55, Iss. 6, pp. 925-944
Open Access | Times Cited: 117
Duration of immune protection of SARS-CoV-2 natural infection against reinfection
Hiam Chemaitelly, Nico Nagelkerke, Houssein H. Ayoub, et al.
Journal of Travel Medicine (2022) Vol. 29, Iss. 8
Open Access | Times Cited: 90
A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease
Melissa M. Higdon, Brian Wahl, Carli B. Jones, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 6
Open Access | Times Cited: 82
Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study
Hiam Chemaitelly, Houssein H. Ayoub, Patrick Tang, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 7, pp. 816-827
Open Access | Times Cited: 70
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
Hiam Chemaitelly, Houssein H. Ayoub, Peter Coyle, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 67
A modeling study to define guidelines for antigen screening in schools and workplaces to mitigate COVID-19 outbreaks
Yong Dam Jeong, Keisuke Ejima, Kwang Su Kim, et al.
Communications Medicine (2025) Vol. 5, Iss. 1
Open Access | Times Cited: 2
Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron
Hiam Chemaitelly, Houssein H. Ayoub, Peter Coyle, et al.
Nature (2025)
Open Access | Times Cited: 2
Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study
Hiam Chemaitelly, Houssein H. Ayoub, Sawsan AlMukdad, et al.
The Lancet Microbe (2022) Vol. 3, Iss. 12, pp. e944-e955
Open Access | Times Cited: 59
Protection against Omicron from Vaccination and Previous Infection in a Prison System
Elizabeth T. Chin, David Leidner, Lauren Lamson, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 19, pp. 1770-1782
Open Access | Times Cited: 56
Covid-19 Vaccine Protection among Children and Adolescents in Qatar
Hiam Chemaitelly, Sawsan AlMukdad, Houssein H. Ayoub, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 20, pp. 1865-1876
Open Access | Times Cited: 55
Waning effectiveness of COVID-19 vaccines
Hiam Chemaitelly, Laith J. Abu‐Raddad
The Lancet (2022) Vol. 399, Iss. 10327, pp. 771-773
Open Access | Times Cited: 53
Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar
Heba N. Altarawneh, Hiam Chemaitelly, Houssein H. Ayoub, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 40
Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study
Heba N. Altarawneh, Hiam Chemaitelly, Houssein H. Ayoub, et al.
EBioMedicine (2023) Vol. 95, pp. 104734-104734
Open Access | Times Cited: 32
Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium
Toni K. Choueiri, Chris Labaki, Ziad Bakouny, et al.
The Lancet Regional Health - Americas (2023) Vol. 19, pp. 100445-100445
Open Access | Times Cited: 31
Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design
Houssein H. Ayoub, Milan Tomy, Hiam Chemaitelly, et al.
American Journal of Epidemiology (2023) Vol. 193, Iss. 6, pp. 883-897
Open Access | Times Cited: 25
SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines
Raju Sunagar, Amit Kumar Singh, Sudeep Kumar
Vaccines (2023) Vol. 11, Iss. 4, pp. 849-849
Open Access | Times Cited: 23
A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease
Melissa M. Higdon, Brian Wahl, Carli B. Jones, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 49
Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar
Hiam Chemaitelly, Houssein H. Ayoub, Sawsan AlMukdad, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 36
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
Hiam Chemaitelly, Houssein H. Ayoub, Sawsan AlMukdad, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 32
Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar
Elias Tayar, Sami Abdeen, Muna Abed Alah, et al.
Journal of Infection and Public Health (2022) Vol. 16, Iss. 2, pp. 250-256
Open Access | Times Cited: 29
Protection of SARS-CoV-2 natural infection against reinfection with the Omicron BA.4 or BA.5 subvariants
Heba N. Altarawneh, Hiam Chemaitelly, Houssein H. Ayoub, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 27
A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3α elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses
James T. Gordy, Yinan Hui, Courtney Schill, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top